Navigation Links
Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
Date:7/30/2008

- Albuferon(R) Phase 3 trial in genotype 1 hepatitis C completes treatment

phase - - Enrollment of patients into screening completed in second LymphoStat-B(R) Phase 3 trial in systemic lupus erythematosus; completion of randomization

expected in August 2008 - - Initial data from Phase 2 HGS-ETR1 multiple myeloma study expected in

third quarter 2008 -

ROCKVILLE, Md., July 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results and key developments for the quarter ended June 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"During the second quarter, we continued to make excellent progress in our Phase 3 trials of Albuferon(R) in chronic hepatitis C and LymphoStat-B(R) in systemic lupus erythematosus," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "Our timelines to Phase 3 results and the filing of marketing applications are on track for both of these key lead products. Our oncology program also continued to show solid progress. For HGS-ETR1, we expect to have data available from our multiple myeloma trial in the third quarter of 2008, and we will soon complete enrollment in our non-small cell lung cancer trial."

FINANCIAL RESULTS

HGS reported increased revenues for the quarter ended June 30, 2008 of $11.6 million, compared with revenues of $9.0 million for the same period in 2007. Revenues included $8.9 million recognized from the Albuferon agreement with Novartis, and $1.6 million in revenue recognized from the LymphoStat-B agreement with G
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
2. Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results
3. New map IDs the core of the human brain
4. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
5. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
6. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
7. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
8. Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus
9. Robots moving closer to humans
10. Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes
11. Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Tris Pharma, a specialty ... today announced that it has been selected as an ... Association,s 2014 Awards for Excellence competition in ... independent panel of judges from SCORE (Counselors to America,s ... will be honored at a gala event to be ...
(Date:8/27/2014)... 27, 2014 After the boom of ... the next beverage craze is going to be the ... formulators can use Stress Relief energy pattern which can ... making of a beverage, including minerals, herbs and liquids. ... channeling that power into rapid recovery and helping to ...
(Date:8/27/2014)... WriteResult, LLC – a premier provider of ... superiority when it comes to meeting the needs of ... of their most recent study closeout on-time and with ... digital writing platform to collect Patient Reported Outcomes electronically ... drew data from a number of assessments including the ...
(Date:8/26/2014)... ANGELES , Aug. 26, 2014  NeuroSigma, Inc., ... company established to develop bioelectronic technologies, today announced that ... with the U.S. Securities and Exchange Commission relating to ... The number of shares to be offered and the ... been determined. Jefferies LLC will act as ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... noses modeled after biological olfaction, the challenge has been ... requisite combinatorial complexity to detect odors in the real ... be manufactured with exact chemical precision and reproducibility. , ... open-access journal PLoS Biology, Joel White, Mary AtKisson, John ...
... Fla., Jan. 22 The Delaware Court of,Chancery today ... brought by a,stockholder of Cryo-Cell International Inc. (OTC Bulletin ... of stockholders held,on July 16, 2007. The court ordered ... a special stockholders meeting to be held on March ...
... Hospitals and healthcare,institutions are challenged to devise ... take place while maintaining Environment of Care,(EC) ... these challenges is,available for download at: ... "Infection Control in the Healthcare,Environment During Construction," ...
Cached Biology Technology:Special Stockholders Meeting to Elect Directors Set for March 4, 2008 2White Paper Details Infection Control Challenges Hospitals Must Address During Construction 2
(Date:8/27/2014)... the greatest risk to Europe based upon a proxy ... researchers using a ,big data, approach to scientific research. ... and Global Health ranked the top 100 pathogens affecting ... a system which, they believe, will help governments across ... of infectious diseases, including as a result of climate ...
(Date:8/27/2014)... . , Charcot-Marie-Tooth ... affecting the peripheral nervous system. Researchers from the Department ... Medicine and University Medical Centre Gttingen have discovered that ... with the disease. These cells enwrap the nerve fibres ... the rapid transfer of electrical impulses. If Schwann cells ...
(Date:8/27/2014)... basic research, a growing focus on translating discoveries ... have earned the Herbert Irving Comprehensive Cancer Center ... NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center ... The grant renews the center,s status as one ... New York City and one of only three ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... vast majority of patients who had a successful ... need mitral valve surgery three years after their ... of the left ventricle (commonly known as reverse ... the Cardiovascular Research Foundations (CRF) nineteenth annual Transcatheter ...
... D.C. October 24, 2007 - The U.S. Senate ... Appropriations Bill (S.1710), including a provision that directs the ... Access Policy by requiring rather than requesting participation by ... House Appropriations Bill, which contains a similar provision, in ...
... Germany-October 24, 2007-Harvard University,s Office of Technology Development ... jointly establish the BASF Advanced Research Initiative. ... and Applied Sciences (SEAS) the initiative will benefit ... throughout the University. Set up as a ...
Cached Biology News:New data shows benefits of MitraClip for patients with mitral regurgitation 2New data shows benefits of MitraClip for patients with mitral regurgitation 3Mandate for public access to NIH-funded research poised to become law 2BASF and Harvard University announce extensive research collaboration 2